Risk of cerebrovascular adverse events in older adults using antipsychotic agents: A propensity-matched retrospective cohort study

Journal of Clinical Psychiatry

Volumn 71, Issue 6, 2010, Pages 689-698

  Mehta, Sandhya ^a   Johnson, Michael L ^a   Chen, Hua ^a   Aparasu, Rajender R ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CYCLOOXYGENASE 2 INHIBITOR; NEUROLEPTIC AGENT; VASOCONSTRICTOR AGENT;

ADVERSE DRUG REACTION; ARTICLE; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; HORMONE SUBSTITUTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; TREATMENT DURATION;

ADULT; AGE FACTORS; AGED; ANTIPSYCHOTIC AGENTS; CEREBROVASCULAR DISORDERS; COHORT STUDIES; DATABASES, FACTUAL; EMERGENCY SERVICE, HOSPITAL; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INCIDENCE; INSURANCE CLAIM REPORTING; MALE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 77953792034     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05817yel     Document Type: Article

References (65)

1. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934-1943. (Pubitemid 41464695)
2. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):CD003476.
3. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.
4. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64(2):134-143. (Pubitemid 36268315)
5. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ. 2004;167(11):1269-1270. (Pubitemid 38594631)
6. Cavazzoni P, Young C, Polzer J, et al. Incidence of cerebrovascular adverse events and mortality during antipsychotic clinical trials of elderly patients with dementia. Proceedings of the 44th annual News Clinical Drugs Evaluation Unit; June 1-4, 2004; Phoenix, AZ.
7. Herrmann N, Lanctôt KL. Do atypical antipsychotics cause stroke? CNS Drugs. 2005;19(2):91-103. (Pubitemid 40321762)
8. Street JS, Clark WS, Gannon KS, et al. The HGEU Study Group. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2000;57(10):968-976.
9. Mazzucco S, Cipriani A, Barbui C, et al. Antipsychotic drugs and cerebrovascular events in elderly patients with dementia: a systematic review. Mini Rev Med Chem. 2008;8(8):776-783.
10. Mazzucco S, Cipriani A, Lintas C, et al. Effect of antipsychotic drugs on cerebrovascular morbidity and mortality: a systematic review. Current Drug Therapy. 2006;1(3):241-248.
11. Herrmann N, Mamdani M, Lanctôt KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry. 2004;161(6):1113-1115. (Pubitemid 38736000)
12. Liperoti R, Gambassi G, Lapane KL, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry. 2005;66(9):1090-1096. (Pubitemid 41442273)
13. Finkel S, Kozma C, Long S, et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr. 2005;17(4):617-629. (Pubitemid 41758766)
14. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study [published online ahead of print January 24, 2005]. BMJ. 2005;330(7489):445. (Pubitemid 40314208)
15. Layton D, Harris S, Wilton LV, et al. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. J Psychopharmacol. 2005;19(5):473-482. (Pubitemid 41392301)
16. Barnett MJ, Wehring H, Perry PJ. Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. J Clin Psychopharmacol. 2007;27(6):595-601. (Pubitemid 351339446)
17. Formiga F, Fort I, Pérez-Castejón JM, et al. Association between risperidone treatment and cerebrovascular adverse events in elderly patients with dementia. J Am Geriatr Soc. 2005;53(8):1446-1448. (Pubitemid 41602503)
18. Kolanowski A, Fick D, Waller JL, et al. Outcomes of antipsychotic drug use in community-dwelling elders with dementia. Arch Psychiatr Nurs. 2006;20(5):217-225. (Pubitemid 44436834)
19. Wang PS, Schneeweiss S, Setoguchi S, et al. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. J Clin Psychopharmacol. 2007;27(6):707-710. (Pubitemid 351339462)
20. Sacchetti E, Trifirò G, Caputi A, et al. Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. J Psychopharmacol. 2008;22(1):39-46.
21. Kleijer BC, van Marum RJ, Egberts ACG, et al. Risk of cerebrovascular events in elderly users of antipsychotics. (published online ahead of print July 17, 2008) J Psychopharmacol. 2009;23(8):909-914.
22. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008;337:a1227.
23. Schneider LS, Tariot PN, Dagerman KS, et al. CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355(15):1525-1538.
24. Allain H, Dautzenberg PHJ, Maurer K, et al. Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment. Psychopharmacology (Berl). 2000a;148(4):361-366. (Pubitemid 30169753)
25. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc. 1999;47(1):30-39. (Pubitemid 29044264)
26. PharMetrics Integrated Database. Datasets. IMS http://www.imshealth.com/ portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid= d7660b6f5aa0210VgnVCM100000ed152ca2RCRD&vgnextchannel= bc42650204850210VgnVCM100000ed152ca2RCRD&vgnextfmt=default. Accessed October 24, 2009.
27. Valuck RJ, Libby AM, Sills MR, et al. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs. 2004;18(15):1119- 1132.
28. Gill SS, Bronskill SE, Normand SLT, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11): 775-786.
29. Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627-632.
30. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs atypical antipsychotic medications. N Engl J Med. 2005;353(22):2335-2341.
31. World Health Organization. ICD-9: International Statistical Classification of Diseases and Relation Health Problems. 9th rev. Geneva, Switzerland: World Health Organization; 1978.
32. Elixhauser A, Steiner CA, Whittington CA, et al. Clinical Classifications for Health Policy Research: Hospital Inpatient Statistics, 1995. Healthcare Cost and Utilization Project, HCUP-3 Research Note. AHCPR Pub. No. 98-0049. Rockville, MD: Agency for Healthcare Research and Quality; 2000.
33. Grobbee DE, Hoes AW. Confounding and indication for treatment in evaluation of drug treatment for hypertension. BMJ. 1997;315(7116):1151-1154.
34. Glynn RJ, Schneeweiss S, Stürmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006;98(3):253-259.
35. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265-2281.
36. Baser O. Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health. 2006;9(6):377-385.
37. Brookhart MA, Schneeweiss S, Rothman KJ, et al. Variable selection for propensity score models. Am J Epidemiol. 2006;163(12):1149-1156.
38. Aparasu RR, Jano E, Johnson ML, et al. Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients. Am Geriatr Pharmacother. 2008;6(4):198-204.
39. Parson LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. http://www2.sas.com/proceedings/sugi26/p214-26.pdf. Accessed March 30, 2009.
40. Feng WW, Jun Y, Xu R, et al. A method/macro based on propensity score and mahalanobis distance to reduce bias in treatment comparison in observational study. http://www.lexjansen.com/pharmasug/2006/publichealthresearch/pr05.pdf. Accessed April 7, 2009.
41. Alexander MT, Kufera JA. Butting Heads on Matched Cohort Analysis Using SAS Software. http://www.nesug.org/proceedings/nesug07/sa/sa01.pdf. Accessed May 1, 2009.
42. Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med. 2008;27(12):2037-2049.
43. Austin PC. Type I error rates, coverage of confidence intervals, and variance estimation in propensity-score matched analysis. Int J Biostat. 2009;5(1). http://www.bepress.com/ijb/vol5/iss1/13/. Accessed April 30, 2010.
44. Gottlieb S. Warnings issued over COX 2 inhibitors in US and UK. BMJ. 2005;330(7481):9.
45. Jones SC. Relative thromboembolic risks associated with COX-2 inhibitors. Ann Pharmacother. 2005;39(7-8):1249-1259.
46. Furie KL, Kelly PJ. Handbook of Stroke Prevention in Clinical Practice. Totowa, NJ: Humana Press; 2004.
47. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120(11):897-902.
48. Fihn SD, Callahan CM, Martin DC, et al. The National Consortium of Anticoagulation Clinics. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med. 1996;124(11):970-979.
49. Stephenson J. FDA orders estrogen safety warnings: agency offers guidance for HRT use. JAMA. 2003;289(5):537-538.
50. Leslie RS. Calculating medication compliance, adherence, and persistence in administrative pharmacy claims database. http://www.wuss.org/proceedings08/ 08WUSS%20Proceedings/papers/anl/anl09.pdf. Accessed April 12, 2009.
51. Dehejia RH, Wahba S. Propensity Score-Matching For nonexperimental causal studies. Rev Econ Stat. 2002;84(1):151-161.
52. Trifirò G, Spina E, Gambassi G. Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile? Pharmacol Res. 2009;59(1):1-12.
53. Ostbye T, Hill G, Steenhuis R. Mortality in elderly Canadians with and without dementia: a 5-year follow-up. Neurology. 1999;53(3):521-526.
54. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.
55. Percudani M, Barbui C, Fortino I, et al. Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. J Clin Psychopharmacol. 2005;25(5):468-470. (Pubitemid 41368370)
56. Herrmann N, Lanctôt KL. Do atypical antipsychotics cause stroke? CNS Drugs. 2005;19(2):91-103.
57. Smith DA, Beier MT. Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypotheses for an underlying mechanism. J Am Med Dir Assoc. 2004;5(2):129-132.
58. Kamijo Y, Soma K, Nagai T, et al. Acute massive pulmonary thromboembolism associated with risperidone and conventional phenothiazines. Circ J. 2003;67(1):46-48.
59. Liperoti R, Gambassi G, Lapane KL, et al. Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Arch Intern Med. 2005;165(6):696-701.
60. Osborn DPJ, Levy G, Nazareth I, et al. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Arch Gen Psychiatry. 2007;64(2):242-249.
61. Lacut K, Le Gal G, Couturaud F, et al. Association between antipsychotic drugs, antidepressant drugs and venous thromboembolism: results from the EDITH case-control study. Fundam Clin Pharmacol. 2007;21(6):643-650. (Pubitemid 350151244)
62. Liperoti R, Pedone C, Lapane KL, et al. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med. 2005;165(22):2677-2682. (Pubitemid 41785068)
63. Chen Y, Guo JJ, Li H, et al. Risk of cerebrovascular events associated with antidepressant use in patients with depression: a population-based, nested case-control study [published online ahead of print January 22, 2008]. Ann Pharmacother. 2008;42(2):177-184.
64. Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. J Clin Psychiatry. 2004;65(12):1642-1653.
65. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ. 2005;330(7488):385. (Pubitemid 40288822)